3Q 2025 Total Revenue of $134.2 Million, a 12% YoY Increase 3Q 2025 GAAP Net Income of $36.4 Million, a 1% YoY Increase 3Q 2025 Adjusted EBITDA (1) of $58.7 Million, a 29% YoY Increase 3Q 2025 Adjusted Net Income (2) of $38.9 Million, an 8% YoY Increase FDA Lot Release of First Yield-Enhanced Production Batches Positions ADMA for Margin Expansion Beginning in 4Q 2025 and Continuing Through 2026 Positive, Statistically... Read More

Conference Call Scheduled for November 5, 2025, at 4:30 p.m. ET RAMSEY, N.J. and BOCA RATON, Fla., Oct. 29, 2025 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), a U.S. based, end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics, today announced that it will report third quarter 2025 financial results on November 5, 2025,... Read More

2Q 2025 Total Revenue of $122.0 Million, a 14% YoY Increase, and a 29% YoY Increase Excluding a Prior Year Non-Recurring Item 2Q 2025 GAAP Net Income of $34.2 Million, a 7% YoY Increase 2Q 2025 Adjusted EBITDA ( 1 ) of $50.8 Million, a 59% YoY Increase Excluding a Prior-Year Non-Recurring Item 2Q 2025 Adjusted Net Income ( 2 ) of $36.0 Million, an 85% YoY Increase Excluding a Prior-Year Non-Recurring Item Initiated... Read More

Conference Call Scheduled for August 6, 2025, at 4:30 p.m. ET RAMSEY, N.J. and BOCA RATON, Fla., July 30, 2025 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), a U.S. based, end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty biologics, today announced that it will report second quarter 2025 financial results on August 6, 2025,... Read More

1Q 2025 Total Revenue of $114.8 Million (Adjusted Total Revenue ( 1 ) of $118.6 Million), a 40% YoY Increase 1Q 2025 GAAP Net Income of $26.9 Million, a 51% YoY Increase 1Q 2025 Adjusted EBITDA ( 2 ) of $47.9 Million, an 81% YoY Increase 1Q 2025 Adjusted Net Income ( 3 ) of $33.3 Million, an 87% YoY Increase 1Q 2025 Total Cash and Receivables Grew to Approximately $171 Million FDA Approved Yield Enhancement Process... Read More

RAMSEY, N.J. and BOCA RATON, Fla., April 30, 2025 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), a U.S. based, end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty biologics, today announced that it will report first quarter 2025 financial results on May 7, 2025, after the U.S. financial markets close. ADMA’s management team will... Read More

Approval Supports Revenue Growth and Margin Expansion Opportunity, and Substantially Increases Peak Production Output Capacity First U.S. Regulatory Approval of Innovative IG Yield Enhancement Process Highlights ADMA’s Uniquely Efficient Internal R&D Engine, Spanning Production and Product Development Capabilities Anticipate Approximately 20% Production Output Enhancement from Same Starting Plasma Volume The 20% Yield... Read More

RAMSEY, N.J. and BOCA RATON, Fla., April 07, 2025 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics, today provided a statement on the recent tariffs put in place and reiterated ADMA’s strategic advantage through fully U.S.-based manufacturing operations,... Read More

FY 2024 Total Revenue of $426.5 Million, a 65% YoY Increase FY 2024 GAAP Net Income of $197.7 Million, Including an $84.3 Million Valuation Allowance Tax Benefit FY 2024 Adjusted EBITDA (1) of $164.6 Million, a 309% YoY Increase FY 2024 Adjusted Net Income ( 2 ) of $119.2 Million, Compared to $0.7 Million in FY 2023, a 16,810% YoY Increase YE 2024 Total Cash Grew to More than $103 Million, Including $60 Million of Debt... Read More

RAMSEY, N.J. and BOCA RATON, Fla., Feb. 28, 2025 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty biologics, today announced Adam Grossman, President and Chief Executive Officer, will participate in a fireside chat at the Raymond James Institutional Investor Conference on March... Read More

RAMSEY, N.J. and BOCA RATON, Fla., Feb. 25, 2025 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty biologics, today announced that it will report fourth quarter and full year 2024 financial results on March 3, 2025, after the U.S. financial markets close. ADMA’s management team... Read More

FY 2024 Preliminary Unaudited Total Revenue of Approximately $417-425 Million, Exceeding Previous Guidance of $415 Million YE 2024 Total Cash Grew to More than $100 Million, an Increase of Approximately $45 Million Q-o-Q, Notwithstanding $30 Million of Debt Organically Discharged During 4Q 2024 Newly Executed High Titer Plasma Supply Contracts Expected to Provide Foundation for Durable ASCENIV Revenue Growth Through Late... Read More

RAMSEY, N.J. and BOCA RATON, Fla., Jan. 07, 2025 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty biologics, today announced that Company management will present at the 43rd Annual J.P. Morgan Healthcare Conference being held in San Francisco, California, January 13-16, 2025.... Read More

Cash on Hand Utilized to Repay $30 Million of Senior Secured Term Loan Facility to Ares Capital Lowers ADMA’s Total Debt to $75 Million, a 29% Reduction Further Supports Earnings Growth Outlook RAMSEY, N.J. and BOCA RATON, Fla., Dec. 20, 2024 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and... Read More

3Q 2024 Total Revenue of $119.8 Million, a 78% Increase Y-o-Y 3Q 2024 GAAP Net Income of $35.9 Million, a 1,300% Increase Y-o-Y 3Q 2024 Adjusted EBITDA ( 1) of $45.4 Million, a 256% Increase Y-o-Y KPMG LLP Engaged as New Independent Registered Public Accounting Firm FY 2024 and 2025 Total Revenue Guidance Increased to More Than $415 Million and $465 Million, Respectively FY 2024 and 2025 GAAP Net Income Guidance Increased to... Read More

RAMSEY, N.J. and BOCA RATON, Fla., Oct. 29, 2024 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty biologics, today announced that it will report third quarter 2024 financial results on November 7, 2024, after the U.S. financial markets close. ADMA’s management team will host a... Read More

RAMSEY, N.J. and BOCA RATON, Fla., Sept. 17, 2024 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty biologics, today announced it will join the S&P SmallCap 600 index, effective prior to the open of trading on Monday, September 23, 2024. The S&P SmallCap 600 seeks to measure the small-cap segment... Read More

RAMSEY, N.J. and BOCA RATON, Fla., Sept. 10, 2024 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty biologics, today announced Adam Grossman, President and Chief Executive Officer, will participate in a fireside chat at the 2024 Cantor Global Healthcare Conference in New York, NY... Read More

Cash on Hand Utilized to Repay $30 Million of Revolving Credit Facility to Ares Capital with No Prepayment Penalties Lowers ADMA’s Total Debt to $105 Million, a 22% Reduction Further Supports Earnings Growth Outlook RAMSEY, N.J. and BOCA RATON, Fla., Aug. 14, 2024 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing,... Read More

2Q 2024 Total Revenue of $107.2 Million, a 78% Increase Y-o-Y 2Q 2024 GAAP Net Income of $32.1 Million, a $38.4 Million Increase Y-o-Y 2Q 2024 Adjusted EBITDA (1) of $44.5 Million, a Nearly 600% Increase Y-o-Y Commercial Scale Production of ADMA’s Innovative Biologics Manufacturing Process Supports a Potential Yield Enhancement of Approximately 20% from Same Starting Plasma FY 2024 and 2025 Total Revenue Guidance Increased... Read More

RAMSEY, N.J. and BOCA RATON, Fla., Aug. 01, 2024 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty biologics, today announced that it will report second quarter 2024 financial results on August 8, 2024, after the U.S. financial markets close. ADMA’s management team will host a... Read More

1Q 2024 Total Revenue of $81.9 Million, a 44% Increase Y-o-Y 1Q 2024 GAAP Net Income of $17.8 Million, a $24.6 Million Increase Y-o-Y 1Q 2024 Adjusted EBITDA ( 1 ) of $26.4 Million, a 970% Increase Y-o-Y FY 2024 and 2025 Total Revenue Guidance Increased to More Than $355 Million and $410 Million, Respectively FY 2024 Net Income Guidance Increased to More Than $85 Million and Adjusted EBITDA Guidance Increased to More Than... Read More

RAMSEY, N.J. and BOCA RATON, Fla., May 02, 2024 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty biologics, today announced that it will report first quarter 2024 financial results on May 9, 2024, after the U.S. financial markets close. ADMA’s management team will host a live... Read More

FDA Approval Provides for Room Temperature (25°C) Storage Conditions for up to 4 Weeks at Any Point During the 36-Month Approved Shelf Life Extends the Prior Room Temperature Storage Allowance for the Full 36-months for ASCENIV and BIVIGAM Provides for Improved Inventory Management and Ease of Product Administration to Patients Approval of Extended Ambient Storage Conditions for ASCENIV & BIVIGAM is Immediately Effective and... Read More

RAMSEY, N.J. and BOCA RATON, Fla., March 05, 2024 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty biologics, today announced Adam Grossman, President and Chief Executive Officer, will participate in a fireside chat at the Raymond James Institutional Investor Conference on March... Read More

RAMSEY, N.J. and BOCA RATON, Fla., Feb. 28, 2024 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics, today announced that Brian Lenz, Executive Vice President, Chief Financial Officer & General Manager, ADMA BioCenters will be transitioning from these positions to a... Read More

4Q 2023 Total Revenue of $73.9 Million; FY 2023 Total Revenue of $258.2 Million 4Q 2023 Adjusted EBITDA ( 1 ) of $18.6 Million; FY 2023 Adjusted EBITDA of $40.3 Million 4Q 2023 Adjusted Net Income ( 2 ) of $8.5 Million; FY 2023 Adjusted Net Income of $0.7 Million FY 2024 and 2025 Total Revenue Guidance Increased to More Than $330 Million and $380 Million, Respectively FY 2024 Net Income Guidance Increased to More Than $65... Read More

RAMSEY, N.J. and BOCA RATON, Fla., Feb. 21, 2024 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty biologics, today announced that it will report fourth quarter and full year 2023 financial results on February 28, 2024, after the U.S. financial markets close. ADMA’s management... Read More

ADMAlytics Combines Generative AI and Machine Learning to Optimize Production Processes ADMA Successfully Utilized ADMAlytics’ New Capabilities for the First Time to Automate and Realize Efficiency Improvements for Commercial Production Plasma Pooling Broader Implementation of ADMAlytics Expected to Provide Efficiencies Across the Organization RAMSEY, N.J. and BOCA RATON, Fla., Feb. 21, 2024 (GLOBE NEWSWIRE) -- ADMA... Read More

4Q 2023 Preliminary Unaudited Total Revenue of $72-74 Million FY 2023 Preliminary Unaudited Total Revenue of $256-258 Million FY 2024 and 2025 Total Revenue Guidance Increased to More than $320 Million and $370 Million, Respectively FY 2024 Net Income Expected to Exceed $60 Million and Adjusted EBITDA ( 1) Expected to be $85 Million Growth Opportunities Targeting Manufacturing and New Pipeline Hyperimmune Globulin to Advance... Read More

New $135 Million Credit Facility Replaces Existing $159 Million Credit Facility, a 15% Decrease in Total Debt Further Supports Rapid Q-o-Q and Y-o-Y Earnings Accretion RAMSEY, N.J. and BOCA RATON, Fla., Dec. 18, 2023 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty... Read More

Signifies the Successful Fulfillment of BIVIGAM’s Post Marketing Commitments as Part of the Original BLA Approval Expanded Label in the U.S. Now Includes Pediatric PI Patients 2 Years of Age and Older RAMSEY, N.J. and BOCA RATON, Fla., Dec. 12, 2023 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and... Read More

RAMSEY, N.J. and BOCA RATON, Fla. and LAUREL, Md., Nov. 16, 2023 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc . (NASDAQ: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today announced that it has received U.S. Food and Drug Administration (“FDA”) approval for its tenth ADMA BioCenters plasma collection... Read More

3Q2023 Total Revenues of $67.3 Million, a 64% Y-o-Y Increase First-Time Positive GAAP Net Income of $2.6 Million First-Time Positive Operating Cash Flow of $12.0 Million, Growing Total Cash Balance to $74.2 Million 3Q2023 Adjusted EBITDA ( 1) Grew to $12.7 Million, a 98% Q-o-Q Increase FY2023 Total Revenue Now Expected to Exceed $250 Million, Increased from $240 Million Adjusted EBITDA and Net Income Growth Expected Over the... Read More

RAMSEY, N.J. and BOCA RATON, Fla., Nov. 01, 2023 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty plasma-derived biologics, today announced that it will report third quarter 2023 financial results on November 8, 2023, after the U.S. financial markets close. ADMA’s management... Read More

2Q2023 Total Revenues of $60.1 Million, a 77% Y-o-Y Increase 2Q2023 Adjusted EBITDA (1) of $6.4 Million, a 160% Q-o-Q Improvement 2Q2023 Adjusted Net Loss (2) of $3.6 Million, a 74% Y-o-Y Improvement FY2023 Total Revenue Now Expected to Exceed $240 Million, Increased from $220 Million Adjusted EBITDA Growth Expected Over the Remainder of 2023 FY2024 and 2025 Total Revenue Guidance Increased to $275 Million and $325 Million... Read More

RAMSEY, N.J. and BOCA RATON, Fla., Aug. 02, 2023 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty plasma-derived biologics, today announced that it will report second quarter financial results on August 9, 2023, after the U.S. financial markets close. ADMA’s management team will... Read More

FDA Approval Supports Corporate Goal of Plasma Supply Self-Sufficiency and Ongoing Revenue Growth Company Remains On-Track to Have All 10 Plasma Collection Centers FDA-Licensed by Year-End 2023 RAMSEY, N.J. and BOCA RATON, Fla. and DALLAS, Ga., July 19, 2023 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing,... Read More

1Q2023 Total Revenues of $57 Million, a 96% Y-o-Y Increase 1Q2023 Net Loss of $6.8 Million, a 73% Y-o-Y Improvement Achieved Milestone First-Time Positive Adjusted EBITDA (1 ) , Totaling $2.5 Million, Earlier Than Forecasted FY2023 Total Revenue Now Expected to Exceed $220 Million, Increased from $210 Million Adjusted EBITDA Growth Expected Over the Remainder of 2023 Conference Call Scheduled for Today at 4:30 p.m. ET... Read More

RAMSEY, N.J. and BOCA RATON, Fla., May 03, 2023 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty plasma-derived biologics, today announced that it will report first quarter 2023 financial results on May 10, 2023, after the U.S. financial markets close. ADMA’s management team... Read More

Reduces Nominal Interest Rate by 1% Provides for Improved Prepayment Flexibility Total Debt Level Unchanged Favorable Amendment Enabled by Strengthened Financial Outlook RAMSEY, N.J. and BOCA RATON, Fla., May 02, 2023 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty... Read More

4Q2022 Total Revenues of $50 Million, a 90% Y-o-Y Increase 4Q2022 Gross Profit of $14 Million, an $11 Million Y-o-Y Increase FY 2023 Total Revenue Expected to Exceed $210 Million First-Time Positive EBITDA Expected No Later than Second Half of 2023 Conference Call Scheduled for Today at 4:30 p.m. ET RAMSEY, N.J. and BOCA RATON, Fla., March 23, 2023 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the... Read More

RAMSEY, N.J. and BOCA RATON, Fla., March 16, 2023 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty plasma-derived biologics, today announced that it will report fourth quarter and full year 2022 financial results on March 23, 2023, after the U.S. financial markets close. ADMA’s... Read More

FDA Approval Supports Corporate Goal of Plasma Supply Self-Sufficiency and Ongoing Revenue Growth Company Remains On-Track to Have All 10 Plasma Collection Centers FDA-Licensed by Year-End 2023 RAMSEY, N.J. and BOCA RATON, Fla. and HAMMOND, La., Feb. 08, 2023 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing,... Read More

Fourth Quarter 2022 Preliminary Unaudited Total Revenues of Approximately $49-$50 Million, an 89% Year-Over-Year Increase Full Year 2022 Preliminary Unaudited Total Revenues of Approximately $153-$154 Million, an 90% Increase Over Full Year 2021 Full Year 2023 Total Revenues are Expected to be $210 Million or More, Representing Approximately 40% Year-Over-Year Growth Rate First-Time Positive EBITDA Expected During Second... Read More

FDA approvals for both ASCENIV and BIVIGAM provide for room temperature (25°C) storage conditions for up to 4 weeks during the first 24 months of the 36-month approved shelf life Provides for improved inventory management and ease of product administration to patients Approval for ambient storage conditions for ASCENIV & BIVIGAM is immediately effective and now commercially available to U.S. healthcare providers RAMSEY, N.J.... Read More

RAMSEY, N.J. and BOCA RATON, Fla., Dec. 09, 2022 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq:ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today announced the closing of its previously announced underwritten public offering of 20,979,020 shares of its common stock at a public offering price of... Read More

RAMSEY, N.J. and BOCA RATON, Fla., Dec. 07, 2022 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq:ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today priced its previously announced underwritten public offering of 20,979,020 shares of its common stock at a public offering price of $2.86 per share,... Read More